AF
FOLD

Allworth Financial’s Amicus Therapeutics FOLD Stock Holding History

Allworth Financial’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75.3K Buy
5,206
+139
+3% +$1.99K ﹤0.01% 2039
2025
Q4 		$72.2K Buy
5,067
+389
+8% +$3.82K ﹤0.01% 1953
2025
Q3 		$36.9K Buy
4,678
+1,246
+36% +$8.87K ﹤0.01% 2311
2025
Q2 		$19.7K Buy
3,432
+3,245
+1,735% +$20.9K ﹤0.01% 2537
2025
Q1 		$1.35K Buy
187
+164
+713% +$1.52K ﹤0.01% 3363
2024
Q4 		$220 Sell
23
-235
-91% -$2.44K ﹤0.01% 3769
2024
Q3 		$2.76K Sell
258
-75
-23% -$817 ﹤0.01% 2824
2024
Q2 		$3.46K Buy
333
+159
+91% +$1.63K ﹤0.01% 2683
2024
Q1 		$2.05K Hold
174
– – ﹤0.01% 2797
2023
Q4 		$2.47K Sell
174
-15
-8% -$170 ﹤0.01% 2585
2023
Q3 		$2.3K Buy
189
+166
+722% +$2.14K ﹤0.01% 2472
2023
Q2 		$289 Hold
23
– – ﹤0.01% 3028
2023
Q1 		$256 Hold
23
– – ﹤0.01% 2958
2022
Q4 		$281 Sell
23
-61
-73% -$687 ﹤0.01% 2737
2022
Q3 		$1K Buy
84
+61
+265% +$680 ﹤0.01% 2374
2022
Q2 		$0 Buy
+23
New +$189 ﹤0.01% 2525

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Allworth Financial's FOLD Position: Q1 2026 in Review

Allworth Financial increased its Amicus Therapeutics (FOLD) stake by 2.7% in Q1 2026, buying an estimated $1.99K and bringing the position to 5,206 shares worth $75.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2039.

Allworth Financial first reported a position in FOLD in Q2 2022 and has held it in 16 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Allworth Financial held 5,206 shares of Amicus Therapeutics worth $75.3K as of Q1 2026.
  • Allworth Financial bought 139 Amicus Therapeutics shares in Q1 2026, an estimated $1.99K.
  • Amicus Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #2039 holding.
  • Allworth Financial first reported a position in Amicus Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.